Development and in vitro evaluation of liposomes and immunoliposomes containing 5-fluorouracil and R-phycoerythrin as a potential phototheranostic system for colorectal cancer

• Raissa Rodrigues Camelo,
• Vivianne Cortez Sombra Vandesmet,
• Octavio Vital Baccallini,
• José de Brito Vieira Neto,
• Thais da Silva Moreira,
• Luzia Kalyne Almeida Moreira Leal,
• Claudia Pessoa,
• Daniel Giuliano Cerri,
• Maria Vitória Lopes Badra Bentley,
• Josimar O. Eloy,
• Ivanildo José da Silva Júnior and
• Raquel Petrilli

Beilstein J. Nanotechnol. 2026, 17, 97–121, doi:10.3762/bjnano.17.7

• stability hampers its clinical use. Thus, the present work aimed to develop co-encapsulated liposomes system for co-delivery of 5-FU and R-PE as theranostic nanosystems for CRC, as well as immunoliposomes targeted with the anti-EGFR monoclonal antibody, cetuximab, as a strategy for targeted delivery to EGFR

• -positive CRC. To the best of our knowledge, this is the first study to report the development and in vitro evaluation of liposomes and immunoliposomes co-encapsulating 5-FU and R-PE. Thus, liposomes containing 25 mg or 50 mg of soybean phosphatidylcholine (SPC), diesterolphosphatidylcholine (DSPC

• in a stable range. From the choice of the 50 mg HSPC liposome, the immunoliposomes were developed. The selected immunoliposomes, composed HSPC/DOPE/Chol/DSPE-PEG-Mal in a ratio of 64:10:22.2:3.7, were named HSPC IM 07. This formulation presented low PDI (0.185 ± 0.01), small vesicle size (99.45

Key for crossing the BBB with nanoparticles: the rational design

• Sonia M. Lombardo,
• Marc Schneider,
• Akif E. Türeli and
• Nazende Günday Türeli

Beilstein J. Nanotechnol. 2020, 11, 866–883, doi:10.3762/bjnano.11.72

• clinical use for the treatment of CNS diseases, although some clinical trials are currently ongoing. A phase-I trial of anti-EGFR-immunoliposomes loaded with doxorubicin, still recruiting, might provide soon clinical information on the ratio between the concentration of doxorubicin in the cerebro-spinal

Dispersion of single-wall carbon nanotubes with supramolecular Congo red – properties of the complexes and mechanism of the interaction

• Anna Jagusiak,
• Barbara Piekarska,
• Tomasz Pańczyk,
• Małgorzata Jemioła-Rzemińska,
• Elżbieta Bielańska,
• Barbara Stopa,
• Grzegorz Zemanek,
• Janina Rybarska,
• Irena Roterman and
• Leszek Konieczny

Beilstein J. Nanotechnol. 2017, 8, 636–648, doi:10.3762/bjnano.8.68

• improve the biocompatibility of nanotubes and increase their retention time in the organism. The retention time of carbon nanotubes is longer than that of PLGA particles or immunoliposomes which are quickly taken up by the reticuloendothelial system cells, thus decreasing the efficiency of drug delivery